CACLP 2025 Express

The 2025 CACLP Medical Technology Expo grandly kicked off on the banks of West Lake in Hangzhou! The Hangzhou International Expo Center transformed into a technological magnet, drawing over 50,000 visitors each day. Through the frontier technology matrix, the world’s foremost intelligent manufacturers gathered under one roof to unveil over a thousand groundbreaking innovations. It is an impressive testament that China’s intelligent manufacturing is ushering in a new era for the global healthcare sector.

HONGAN’s iMC Ge series fully automated hematology analyzer made its groundbreaking debut! The dual-booth strategy between HONGAN and Sansure Biotech ignited an irresistible tech buzz at CACLP. In a coordinated effort, HONGAN’s main exhibition area and Sansure Biotech’s joint booth staged an immersive blood testing revolution showcase, drawing more than 10,000 visitors in a single day.

Professor Kang Xixiong, Chair of the Point-of-Care Testing (POCT) Subcommittee of the China Association for Medical Devices Industry and Professor at Beijing Tiantan Hospital, Capital Medical University, visited Sansure Biotech’s booth to attend the launch ceremony for the new portable multifunctional analyzer and address the audience. Joining him for the exchange were Mr. Wang Haixiao, Senior Vice President of Sansure Biotech and Chairman of HONGAN, Mr. Song Jian, Director and General Manager of HONGAN, and Mr. Richard Ni, Director of HONGAN’s Marketing Center.

At the launch event of HONGAN’s iMC Ge-m22i portable multifunctional analyzer, Professor Kang Xixiong passionately proclaimed that the key to overcoming challenges associated with tiered diagnostics and treatment lies in building new digital infrastructure at the grassroots level. He called for empowering grassroots clinics with point-of-care testing technology, equipping them with intelligent equipment, migrating village doctors’ and clinics’ capabilities onto the cloud, and enabling residents to access high-quality, inclusive medical services right in their own neighborhood.

Mr. Song Jian underscored that “the strategic synergy with Sansure Biotech will turbocharge innovation in grassroots medical equipment.” Drawing on Sansure Biotech’s industrialization platform for technological empowerment and its profound channel expertise, HONGAN has comprehensively upgraded and iterated the R&D capabilities. By merging Sansure Biotech’s world-leading molecular diagnostic technologies with HONGAN’s innovation-to-market capabilities, the company is set to launch more inclusive equipment solutions over the next three years. The company aims to translate technological innovations into capillary-level applications in grassroots diagnostics and treatment.

At the product launch event, Mr. Richard Ni presented an in-depth explanation of the core values behind the iMC Ge-m22i series: built on a five-dimensional evolution matrix - “Comprehensive, Compact, Rapid, Robust, and Multifunctional” - to redefine the standard for point-of-care testing in grassroots settings. The equipment marks a significant breakthrough by providing whole-blood test results in just two minutes. When paired with HONGAN’s real-time updated clinical database of over ten million entries, it builds a formidable competitive edge in “sample in-result out” precision diagnostics. For the first time, primary-care physicians can access decision-support capabilities that rival those of central laboratories.